Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes - PubMed
3 hours ago
- #obesity
- #semaglutide
- #weight management
- The study conducted an indirect treatment comparison (ITC) between oral semaglutide 25 mg and subcutaneous (s.c.) semaglutide 2.4 mg for weight loss in adults with obesity or overweight, using data from the OASIS 4 and STEP 1 trials.
- Results indicated comparable efficacy between both formulations across weight loss outcomes, including percentage body weight change and proportions achieving specific weight loss thresholds (≥5%, ≥10%, ≥15%, ≥20%), with differences not clinically relevant.
- Safety profiles were broadly similar, and the findings support therapeutic equivalence, suggesting both oral and s.c. semaglutide are effective options for weight management in this population.